NCT02483624View on ClinicalTrials.gov

3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
SLE
Interventions
DRUG

BR-DIM

DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.

DRUG

Placebo

Placebo

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER